prognosis. Data for metastatic chromophobe RCC (ChRCC) with SF are limited. We studied
clinical outcomes and genomic features in this setting. Patients and Methods We performed
a retrospective review of newly diagnosed metastatic ChRCC patients; end points included
overall survival (OS), time to treatment failure (TTF), and time to metastatic recurrence (TTR)
after nephrectomy for localized disease. A subset of patients underwent next-generation …